Key result
Culturally adapted pharmacist-supported HF day-hospitals linked to fewer readmissions and better GDMT in remote settings.
Why the study?
Does a culturally adapted, pharmacist-supported HF day-hospital programme reduce 12-month HF rehospitalisation in adults with heart failure?
Observational (n=424)
Yes
Does a culturally adapted, pharmacist-supported HF day-hospital programme reduce 12-month HF rehospitalisation in adults with heart failure?
Answers are grounded in this paper and cite their sources.
A culturally adapted, pharmacist-supported HF day-hospital model significantly reduced HF rehospitalisations and improved guideline-directed medical therapy uptake in a remote, high-risk setting.
BACKGROUND: Reducing hospitalisations in heart failure (HF) requires organisational models for rapid optimisation, education and structured follow-up. Evidence on complex programmes in outermost or underserved regions and on the mechanisms through which they achieve their effects remains limited. METHODS: We conducted a convergent mixed-methods evaluation of an anonymised, culturally adapted, pharmacist-supported HF day-hospital programme implemented across two sites in an insular remote European region. The quantitative component was a self-controlled before-after study including all adults attending at least one visit between 1 January 2017 and 31 December 2021 (n=424). The primary outcome was 12-month HF rehospitalisation after versus before enrolment. Secondary outcomes were HF-related bed-days, extended 24-month utilisation, overall survival and optimisation of guideline-directed medical therapy, including quadruple therapy. The qualitative component comprised semi-structured interviews with 10 stakeholders, analysed thematically and integrated with quantitative findings. RESULTS: Using a person-time approach with post-index follow-up censored at death and capped at 12 months, HF rehospitalisation incidence rates decreased from 0.427 (95% CI 0.367 to 0.494) to 0.164 (95% CI 0.127 to 0.207) events per patient-year (incidence rate ratio (IRR) 0.38, 95% CI 0.30 to 0.48). HF bed-days rates decreased from 4.96 (95% CI 4.75 to 5.18) to 1.77 (95% CI 1.64 to 1.90) bed-days per patient-year (IRR 0.43, 95% CI 0.28 to 0.64). Overall survival was 96.0% at 12 months and 91.5% at 24 months. The programme achieved substantial optimisation of core HF therapies and uptake of quadruple therapy. Qualitative findings highlighted enabling mechanisms-multidisciplinary coordination, dedicated infrastructure, pharmacist-supported and nurse-supported titration, bilingual education and engaged leadership-and vulnerabilities including workforce constraints, telemonitoring instability and variable hospital-community integration. CONCLUSIONS: In this high-risk, remote setting, this pharmacist-supported, culturally adapted HF day-hospital model was associated with major reductions in HF rehospitalisations and strong implementation of contemporary therapy, supporting integrated, context-sensitive organisational models to improve HF care quality and equity.
No takes yet. Share an insight, caveat, or question.
Taranzano et al. (2026) conducted an observational in Heart failure (HF) (n=424). Culturally adapted, pharmacist-supported HF day-hospital programme vs. Before enrolment (self-controlled) was evaluated on 12-month HF rehospitalisation after versus before enrolment (IRR 0.38, 95% CI 0.30 to 0.48). A culturally adapted, pharmacist-supported heart failure day-hospital program reduced HF rehospitalisations from 0.427 to 0.164 events per patient-year.
Synapse has enriched 10 related papers. Consider them for comparative context: